Get the latest news, insights, and market updates on ANGO (AngioDynamics, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
AngioDynamics to Report Fiscal 2026 Second Quarter Results on January 6, 2026
LATHAM, N.Y., December 23, 2025--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the second quarter of fiscal year 2026 before the market open on Tuesday, January 6, 2026. The Company’s management will host a conference call at 8:00 am ET the same day t Dec 23, 2025 - $ANGO
AngioDynamics to Present at the 44th Annual J.P. Morgan Healthcare Conference
LATHAM, N.Y., December 22, 2025--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced, that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 14, Dec 22, 2025 - $ANGO
AngioDynamics to Participate in the UBS Global Healthcare Conference
LATHAM, N.Y., October 27, 2025--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced, that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the UBS Global Healthcare Conference at 8:00 a.m. ET on Monday, Nov Oct 27, 2025 - $ANGO
H.C. Wainwright Reaffirms Buy Rating on AngioDynamics (ANGO) After Strong Q1 Performance
AngioDynamics, Inc. (NASDAQ:ANGO) is one of billionaire Steve Cohen’s small-cap stock picks with huge upside potential. On October 6, H.C. Wainwright reiterated its Buy rating on AngioDynamics (NASDAQ:ANGO) with a price target of $16, following robust fiscal Q1 2026 results. The company posted $75.7 million in net sales, up 12.2% year-over-year, driven by a 26.1% […] Oct 26, 2025 - $ANGO
AngioDynamics’ NanoKnife® System Named to TIME’s 2025 Best Inventions List
LATHAM, N.Y., October 13, 2025--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that its NanoKnife System has been selected as one of TIME's 2025 Best Inventions. The annual list celebrates groundbreaking products and technologies that are transforming how people live, work, and receive care. Oct 13, 2025 - $ANGO
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple